Cargando…

Transforming growth factor-β1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition

BACKGROUND: COPD is a common disease characterized by respiratory airflow obstruction. TGF-β1 and SMAD pathway is believed to play a role in COPD pathogenesis by driving epithelial mesenchymal transition (EMT). METHODS: We investigated TGF-β1 signalling and pSmad2/3 and Smad7 activity in resected sm...

Descripción completa

Detalles Bibliográficos
Autores principales: Brake, Samuel James, Lu, Wenying, Chia, Collin, Haug, Greg, Larby, Josie, Hardikar, Ashutosh, Singhera, Gurpreet K., Hackett, Tillie L., Eapen, Mathew Suji, Sohal, Sukhwinder Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331458/
https://www.ncbi.nlm.nih.gov/pubmed/37435075
http://dx.doi.org/10.3389/fimmu.2023.1216506
_version_ 1785070257134632960
author Brake, Samuel James
Lu, Wenying
Chia, Collin
Haug, Greg
Larby, Josie
Hardikar, Ashutosh
Singhera, Gurpreet K.
Hackett, Tillie L.
Eapen, Mathew Suji
Sohal, Sukhwinder Singh
author_facet Brake, Samuel James
Lu, Wenying
Chia, Collin
Haug, Greg
Larby, Josie
Hardikar, Ashutosh
Singhera, Gurpreet K.
Hackett, Tillie L.
Eapen, Mathew Suji
Sohal, Sukhwinder Singh
author_sort Brake, Samuel James
collection PubMed
description BACKGROUND: COPD is a common disease characterized by respiratory airflow obstruction. TGF-β1 and SMAD pathway is believed to play a role in COPD pathogenesis by driving epithelial mesenchymal transition (EMT). METHODS: We investigated TGF-β1 signalling and pSmad2/3 and Smad7 activity in resected small airway tissue from patients with; normal lung function and a smoking history (NLFS), current smokers and ex-smokers with COPD GOLD stage 1 and 2 (COPD-CS and COPD-ES) and compared these with normal non-smoking controls (NC). Using immunohistochemistry, we measured activity for these markers in the epithelium, basal epithelium, and reticular basement membrane (RBM). Tissue was also stained for EMT markers E-cadherin, S100A4 and vimentin. RESULTS: The Staining of pSMAD2/3 was significantly increased in the epithelium, and RBM of all COPD groups compared to NC (p <0.0005). There was a less significant increase in COPD-ES basal cell numbers compared to NC (p= 0.02). SMAD7 staining showed a similar pattern (p <0.0001). All COPD group levels of TGF-β1 in the epithelium, basal cells, and RBM cells were significantly lower than NC (p <0.0001). Ratio analysis showed a disproportionate increase in SMAD7 levels compared to pSMAD2/3 in NLFS, COPD-CS and COPD-ES. pSMAD negatively correlated with small airway calibre (FEF(25–75%); p= 0.03 r= -0.36). EMT markers were active in the small airway epithelium of all the pathological groups compared to patients with COPD. CONCLUSION: Activation of the SMAD pathway via pSMAD2/3 is triggered by smoking and active in patients with mild to moderate COPD. These changes correlated to decline in lung function. Activation of the SMADs in the small airways is independent of TGF-β1, suggesting factors other than TGF-β1 are driving these pathways. These factors may have implications for small airway pathology in smokers and COPD through the process of EMT, however more mechanistic work is needed to prove these correlations.
format Online
Article
Text
id pubmed-10331458
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103314582023-07-11 Transforming growth factor-β1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition Brake, Samuel James Lu, Wenying Chia, Collin Haug, Greg Larby, Josie Hardikar, Ashutosh Singhera, Gurpreet K. Hackett, Tillie L. Eapen, Mathew Suji Sohal, Sukhwinder Singh Front Immunol Immunology BACKGROUND: COPD is a common disease characterized by respiratory airflow obstruction. TGF-β1 and SMAD pathway is believed to play a role in COPD pathogenesis by driving epithelial mesenchymal transition (EMT). METHODS: We investigated TGF-β1 signalling and pSmad2/3 and Smad7 activity in resected small airway tissue from patients with; normal lung function and a smoking history (NLFS), current smokers and ex-smokers with COPD GOLD stage 1 and 2 (COPD-CS and COPD-ES) and compared these with normal non-smoking controls (NC). Using immunohistochemistry, we measured activity for these markers in the epithelium, basal epithelium, and reticular basement membrane (RBM). Tissue was also stained for EMT markers E-cadherin, S100A4 and vimentin. RESULTS: The Staining of pSMAD2/3 was significantly increased in the epithelium, and RBM of all COPD groups compared to NC (p <0.0005). There was a less significant increase in COPD-ES basal cell numbers compared to NC (p= 0.02). SMAD7 staining showed a similar pattern (p <0.0001). All COPD group levels of TGF-β1 in the epithelium, basal cells, and RBM cells were significantly lower than NC (p <0.0001). Ratio analysis showed a disproportionate increase in SMAD7 levels compared to pSMAD2/3 in NLFS, COPD-CS and COPD-ES. pSMAD negatively correlated with small airway calibre (FEF(25–75%); p= 0.03 r= -0.36). EMT markers were active in the small airway epithelium of all the pathological groups compared to patients with COPD. CONCLUSION: Activation of the SMAD pathway via pSMAD2/3 is triggered by smoking and active in patients with mild to moderate COPD. These changes correlated to decline in lung function. Activation of the SMADs in the small airways is independent of TGF-β1, suggesting factors other than TGF-β1 are driving these pathways. These factors may have implications for small airway pathology in smokers and COPD through the process of EMT, however more mechanistic work is needed to prove these correlations. Frontiers Media S.A. 2023-06-26 /pmc/articles/PMC10331458/ /pubmed/37435075 http://dx.doi.org/10.3389/fimmu.2023.1216506 Text en Copyright © 2023 Brake, Lu, Chia, Haug, Larby, Hardikar, Singhera, Hackett, Eapen and Sohal https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Brake, Samuel James
Lu, Wenying
Chia, Collin
Haug, Greg
Larby, Josie
Hardikar, Ashutosh
Singhera, Gurpreet K.
Hackett, Tillie L.
Eapen, Mathew Suji
Sohal, Sukhwinder Singh
Transforming growth factor-β1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition
title Transforming growth factor-β1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition
title_full Transforming growth factor-β1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition
title_fullStr Transforming growth factor-β1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition
title_full_unstemmed Transforming growth factor-β1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition
title_short Transforming growth factor-β1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition
title_sort transforming growth factor-β1 and smad signalling pathway in the small airways of smokers and patients with copd: potential role in driving fibrotic type-2 epithelial mesenchymal transition
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331458/
https://www.ncbi.nlm.nih.gov/pubmed/37435075
http://dx.doi.org/10.3389/fimmu.2023.1216506
work_keys_str_mv AT brakesamueljames transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition
AT luwenying transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition
AT chiacollin transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition
AT hauggreg transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition
AT larbyjosie transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition
AT hardikarashutosh transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition
AT singheragurpreetk transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition
AT hacketttilliel transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition
AT eapenmathewsuji transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition
AT sohalsukhwindersingh transforminggrowthfactorb1andsmadsignallingpathwayinthesmallairwaysofsmokersandpatientswithcopdpotentialroleindrivingfibrotictype2epithelialmesenchymaltransition